Publication date: Feb 01, 2025
This article provides a comprehensive review of the impact of B-cell-directed therapy on severe acute respiratory syndrome coronavirus 2 vaccine immunity, focusing on its implications in autoimmune inflammatory rheumatic diseases (AIIRD). Rituximab (RTX) is the primary B-cell-depleting drug that has been studied in AIIRD and is the focus of this review. We review the pivotal role of B cells in vaccine response and propose strategies to manage and predict vaccine responses in B-cell-depleted individuals. We highlight the need to strategize patients into distinct groups when predicting vaccine responses and developing guidelines to ensure optimal outcomes for RTX-treated patients.
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Coronavirus Disease 2019 |
disease | IDO | cell |
disease | MESH | rheumatic diseases |
drug | DRUGBANK | Rituximab |
drug | DRUGBANK | Resiniferatoxin |
disease | IDO | role |
disease | MESH | Autoimmune Diseases |
Original Article
(Visited 2 times, 1 visits today)